Early Intervention Strategies: MIGS Devices for Mild to Moderate Primary Open-Angle Glaucoma

In the USA, the micro-invasive glaucoma surgery (MIGS) devices market has gained prominence as a viable glaucoma treatment option. The imperative to lower intraocular pressure (IOP) to halt glaucoma progression has historically led to surgical and nonsurgical methods, each with limitations. MIGS emerges as a promising solution, especially when combined with cataract surgery for mild to moderate primary open-angle glaucoma. This safe and efficient approach addresses existing challenges, offering early intervention possibilities and fostering market growth.

Access Full Report @ https://www.databridgemarketresearch.com/es/reports/usa-micro-invasive-glaucoma-surgery-migs-devices-market

Data Bridge Market Research analyses that the USA Micro Invasive Glaucoma Surgery (MIGS) Devices Market which is USD 537.32 million in 2022, is expected to reach USD 5,519.27 million by 2030, at a CAGR of 33.8% during the forecast period 2023 to 2030. Surgeons' endorsement of MIGS devices stems from favorable outcomes and efficient procedures. This driver propels the USA micro-invasive glaucoma surgery (MIGS) devices market as doctors gravitate toward effective and secure treatment options, bolstering their widespread adoption

Key Findings of the Study

The expanding demographic of elderly individuals is expected to drive the market's growth rate

The expanding demographic of elderly individuals, who are more susceptible to glaucoma, fuels the demand for accessible and patient-centric solutions such as micro-invasive glaucoma surgery (MIGS) devices. As the aging population seeks effective treatments that prioritize comfort and minimal invasiveness, MIGS devices gain prominence. This driver aligns with the imperative to address the unique needs of aging patients, propelling the USA MIGS devices market's growth and relevance.

Report Scope and Market Segmentation

Segment Analysis:

The micro invasive glaucoma surgery (MIGS) devices market is segmented on the basis of target, product, surgery type, distribution channel, and end user.

• On the basis of product, the micro invasive glaucoma surgery (MIGS) devices market is segmented into MIGS stents, MIGS shunts, and others.
• On the basis of target, the micro invasive glaucoma surgery (MIGS) devices market is segmented into trabecular meshwork suprachoroidal space subconjunctival filtration and reducing aqueous production.
• On the basis of surgery type, the micro invasive glaucoma surgery (MIGS) devices market is segmented into glaucoma in conjunction with cataract and stand-alone glaucoma.
• On the basis of end user, the micro invasive glaucoma surgery (MIGS) devices market is segmented into hospital outpatient departments (HOPD), ophthalmology clinics, ambulatory surgery centers (ascs), and others.
• On the basis of distribution channel, the micro invasive glaucoma surgery (MIGS) devices market is segmented into direct tender and retail sales.

Major Players

Data Bridge Market Research recognizes the following companies as the major USA micro invasive glaucoma surgery (MIGS) devices market  players in USA micro invasive glaucoma surgery (MIGS) devices market  are Glaukos Corporation (U.S.), Ivantis Inc. (U.S), AbbVie Inc. (U.S.), Ellex (U.S.), Alcon (Switzerland), BVI (U.S.), Johnson and Johnson Surgical Vision Care Inc. (U.S.), Microsurgical technology (U.S.), Molteno Ophthalmic Ltd. (New Zealand),

Market Developments

• In 2022, Glaukos embarked on a Phase II clinical trial for GLK-301 targeting dry eye disease. This milestone marks the enrollment of the first patient, showcasing Glaukos' commitment to innovation. Pending regulatory approval, the drug's potential to address dry eye disease could reshape Glaukos' business landscape, offering novel solutions for patients and strengthening its position in the market.
• In 2022, Alcon completed the acquisition of Ivantis, a pioneer behind the Hydrus Microstent for minimally invasive glaucoma surgery (MIGS). By adding this innovative surgical device to its repertoire, Alcon strengthens its presence in the eye surgery domain. This strategic move augments Alcon's offerings, underscoring its commitment to advancing glaucoma treatment options and patient outcomes.
• In January 2022, Alcon solidified its stature in vision care by acquiring Aerie Pharmaceuticals, Inc. This strategic move amplified Alcon's influence in the ophthalmic pharmaceutical realm, enhancing its commercial product range and developmental pipeline. The acquisition underscores Alcon's commitment to expanding its offerings and advancing eye care solutions for a broader spectrum of patients.
• In October 2022, Alcon successfully integrated Ivantis, Inc. into its global surgical portfolio, incorporating the Hydrus Microstent-a minimally invasive glaucoma surgery (MIGS) device. Engineered to reduce eye pressure in open-angle glaucoma patients alongside cataract surgery, this addition strengthens Alcon's surgical capabilities. The acquisition exemplifies Alcon's dedication to innovating treatments and bolstering its position in the eye healthcare arena.

For more detailed information about the USA micro invasive glaucoma surgery (MIGS) devices market report, click here – https://www.databridgemarketresearch.com/es/reports/usa-micro-invasive-glaucoma-surgery-migs-devices-market